Prime Medicine, Inc.
PRME
$3.73
$0.061.50%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.90% | 3.82% | -1.35% | -22.74% | 19.50% |
| Total Depreciation and Amortization | -0.27% | 0.91% | 9.65% | -0.99% | 10.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.63% | 48.89% | -2.44% | 13.12% | -0.35% |
| Change in Net Operating Assets | 89.82% | 11.13% | 107.16% | -115.66% | 186.13% |
| Cash from Operations | -6.33% | 15.39% | 15.24% | -400.75% | 162.69% |
| Capital Expenditure | -17.41% | 84.29% | 35.09% | -35.23% | -40.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.15% | -2,215.47% | 109.58% | -190.56% | -3.05% |
| Cash from Investing | 130.75% | -3,424.50% | 105.80% | -198.94% | -4.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.59% | 70,332.99% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -100.00% | -- | -- |
| Cash from Financing | -99.61% | 73,378.68% | -96.72% | 599,900.00% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.54% | 145.76% | 57.57% | -240.47% | 2.47% |